Biotech Values

[oc631]

And that's already in Phase II, right? So really my earlier estimate for a drug just entering the clinic must be a year or two optimistic.

Now that I think about it the 2016 filing date would be for INX-189/PegRiba in GT2/GT3 patients so yes your timeline is too optimistic. The 12-week PK safety data in humans will be released 1H/12 and phase 2 oral testing with Riba should begin around the same time.